Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or California for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to California only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. California (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Luke Dreisbach (NPI 1831109792)

Field	Value
Entity Type	Individual
Organization	Luke Dreisbach
Address	34490 Bob Hope Dr.
City	Rancho Mirage
State	CA
ZIP	92270
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	August 9, 2006

Payer Source	Total Paid
Medicare	$9.8M
Medicaid	$0

Key Findings

This provider’s billing footprint is effectively single-payer Medicare: lifetime Medicare revenue is $9.8M while there is no Medicaid billing on file. The absence of any Medicaid claims means analyses of payer mix and access should treat this as a Medicare-dominant practice rather than a dual-payer operation.

Revenue is highly concentrated in a small set of oncology biologics: the precomputed top three Medicare codes account for 57.3% of this provider’s total Medicare revenue, driven by J9271 ($3.6M), J9144 ($985K) and J9022 ($870.9K). All three codes are high-cost injectable oncology therapies (pembrolizumab, daratumumab, atezolizumab), indicating a practice model centered on administering advanced anticancer immunotherapies.

The provider shows national-level dominance on specific drugs: J9271 ranks #2 of 1841 providers nationally (100th percentile; extreme outlier, far above typical national volume for this code), and Q5118 ranks #1 of 161 providers nationally (100th percentile; extreme outlier). These rank/percentile labels indicate this clinician is an unusually large national allocator of certain biologic injectables compared with peers.

Infusion and chemotherapy administration are material service lines: high-percentile procedure codes include 96413 (1.5K claims, $172.1K revenue, ranks #15 of 7514 providers nationally; 100th percentile; extreme outlier), 96417 (627 claims, $35.1K revenue, ranks #4 of 3014 providers nationally; 100th percentile; extreme outlier) and G0498 (176 claims, $25.9K revenue, ranks #14 of 896 providers nationally; 98th percentile; extreme outlier). Combined with office E/M volume such as 99214 (2.5K claims, $251K revenue) this pattern is consistent with an on-site infusion clinic delivering both chemotherapy and follow-up visits.

Supportive care and adjunct biologics are also prominent in the mix: J0897 (denosumab) produced $810K in revenue from 45K claims and is reported as an extreme outlier, Q5122 (pegfilgrastim-apgf biosimilar) produced $311.3K and ranks #2 of 239 providers (100th percentile; extreme outlier), and J1569 (immune globulin) contributed $355.3K (90th percentile; typical, unremarkable). These entries show the practice not only delivers primary oncology agents but also substantial supportive therapies used in cancer care.

There are notable high-volume, low-unit-payment patterns that warrant attention in utilization review: J1439 (ferric carboxymaltose) appears with 249.8K claims at $1 avg paid/claim for $249.8K total revenue and is labeled an extreme outlier. This combination of very large claim counts with low per-claim payment suggests frequent, low-dollar billing activity for that code relative to peers and should be interpreted as an operational pattern rather than an allegation of impropriety.

Tenure and scale reinforce an established oncology specialty: the NPI was enumerated on 2006-08-09 (~20 years ago), and the provider has accumulated $9.8M in Medicare revenue over their lifetime. Long enrollment combined with concentrated, high-dollar oncology and infusion billing is consistent with a mature, specialized practice that has built significant Medicare-volume in its service lines.

Across a broad set of oncology drugs and administration codes this provider frequently ranks in high percentiles: examples include J9144 (#26 of 615; 96th percentile; notably above typical national volume), J9022 (#2 of 39; 97th percentile; notably above typical national volume), and multiple administration codes listed as extreme outliers. Taken together, the rank and percentile pattern indicates this clinician is a major national outlier for the delivery of specific cancer biologics and infusion services rather than a modest regional participant.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

76 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	84,510	$40	$3.6M
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	25,920	$40	$985K
J9022	Injection, atezolizumab, 10 mg	13,610	$60	$870.9K
J0897	Injection, denosumab, 1 mg	45,000	$20	$810K
J9299	Injection, nivolumab, 1 mg	26,100	$20	$626.4K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	10,150	$40	$355.3K
Q5122	Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg	3,380	$90	$311.3K
J9264	Injection, paclitaxel protein-bound particles, 1 mg	29,800	$10	$298K
Q5118	Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg	12,590	$20	$289.6K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	2,460	$100	$251K

Showing 1–10 of 76

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 76 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. California Distribution

Luke Dreisbach — 15 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — California

Full comparison — all codes billed, vs. state median

76 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	1	140	13,100	$40	$653.5K
J9144	9	40	13,860	$40	$631.4K
J9022	1	10	8,900	$60	$568.7K
J9299	13	40	21,000	$20	$538.5K
J9264	4	10	24,150	$10	$350.2K
J1569	10	40	4,560	$40	$303.5K
Q5118	1	10	5,810	$20	$122.5K
J0897	3	1,030	3,060	$20	$91.4K
Q5122	1	10	550	$90	$72.5K
Q5119	4	30	1,940	$20	$66.6K

Showing 1–10 of 76

Related Providers

Other providers that share a Tax Identification Number (TIN) with Luke Dreisbach, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Amy Law	CA	Hematology & Oncology Physician	$4M	$0
Mark Carmichael	CA	Hematology & Oncology Physician	$3.1M	$0
Philip Dreisbach	CA	Hematology & Oncology Physician	$1.6M	$0

Nearby Providers

Other providers in the same ZIP code as Luke Dreisbach, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Eisenhower Medical Center	CA	General Acute Care Hospital	$0	$98M
Tobias Moeller-bertram Md Corporation	CA	Pain Medicine (Anesthesiology) Physician	$0	$49.2M
Tobias Moeller-bertram, Md Corporation Desert Clinic Pain Institute	CA	Pain Medicine Physician	$0	$47.2M
Empire Vein & Vascular Specialists	CA	Vascular Surgery Physician	$0	$32M
Mirage Endoscopy Center, L.P.	CA	Ambulatory Surgical Clinic/Center	$1.6M	$1M
Camille Harrison	CA	Ophthalmology Physician	$2.4M	$0
Timothy Jochen	CA	Procedural Dermatology Physician	$2.3M	$0
Rupinder Mann	CA	Geriatric Medicine (Internal Medicine) Physician	$1M	$831K
Pushpinder Sivia	CA	Vascular Surgery Physician	$1.9M	$0
Josephine Nguyen	CA	Diagnostic Radiology Physician	$1.5M	$0

Luke Dreisbach — Billing Profile & Reimbursement Data

Sign up for Luke Dreisbach — Billing Profile & Reimbursement Data policy alerts

Luke Dreisbach — Billing Profile & Reimbursement Data

Sign up for Luke Dreisbach — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References